Esperion Therapeutics, Inc.
NASDAQ:ESPR
2.24 (USD) • At close December 23, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 116.334 | 75.475 | 78.447 | 227.547 | 148.364 | 184.474 | 0 | 0 | 0 | 0 | 4,977.012 | 0 | 0 | 0 | 0 | 0.002 | 0 |
| Cost of Revenue
| 43.267 | 26.967 | 14.217 | 2.392 | 175.611 | 0.265 | 0.258 | 0.252 | 0.236 | 0 | 0 | 0 | 0 | 0 | 0 | 0.786 | 0.683 |
| Gross Profit
| 73.067 | 48.508 | 64.23 | 225.155 | -27.247 | 184.209 | -0.258 | -0.252 | -0.236 | 0 | 4,977.012 | 0 | 0 | 0 | 0 | -0.784 | -0.683 |
| Gross Profit Ratio
| 0.628 | 0.643 | 0.819 | 0.989 | -0.184 | 0.999 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | -392 | 0 |
| Reseach & Development Expenses
| 86.107 | 118.927 | 105.975 | 146.936 | 175.611 | 171.488 | 147.603 | 57.868 | 29.802 | 25.302 | 16.014 | 7.998 | 7.808 | 21.991 | 21.454 | 21.789 | 8.484 |
| General & Administrative Expenses
| 126.923 | 97.782 | 171.285 | 180.315 | 65.854 | 33.097 | 21.379 | 18.282 | 20.238 | 10.922 | 6.744 | 2.206 | 2.357 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 15.6 | 11.3 | 13.7 | 19.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 142.523 | 109.082 | 184.985 | 199.615 | 65.854 | 33.097 | 21.379 | 18.282 | 20.238 | 10.922 | 6.744 | 2.206 | 2.357 | 5.955 | 5.023 | 2.949 | 2.518 |
| Other Expenses
| 0 | 2.652 | 3.975 | 0.515 | 4.056 | 2.775 | 2.192 | 1.548 | 0.776 | 0.119 | 0.194 | -0.084 | -0.076 | 0 | 0 | 4.999 | 3.201 |
| Operating Expenses
| 228.63 | 228.009 | 290.96 | 346.551 | 241.465 | 204.585 | 168.982 | 76.15 | 50.04 | 36.224 | 22.759 | 10.204 | 10.164 | 29.237 | 29.33 | 26.788 | 11.685 |
| Operating Income
| -155.563 | -179.501 | -226.73 | -121.396 | -93.101 | -204.585 | -168.982 | -76.15 | -50.04 | -36.224 | -22.759 | -10.204 | -10.164 | -27.946 | -27.316 | -27.572 | -12.368 |
| Operating Income Ratio
| -1.337 | -2.378 | -2.89 | -0.533 | -0.628 | -1.109 | 0 | 0 | 0 | 0 | -0.005 | 0 | 0 | 0 | 0 | -13,786 | 0 |
| Total Other Income Expenses Net
| -53.685 | -54.158 | -42.378 | -22.155 | -4.064 | 2.775 | 1.994 | 1.172 | 0.256 | -0.151 | -3.329 | -1.538 | -0.653 | -0.78 | 2.385 | -3.799 | 0 |
| Income Before Tax
| -209.248 | -233.659 | -269.108 | -143.551 | -97.165 | -201.81 | -166.988 | -74.978 | -49.784 | -36.375 | -26.088 | -11.742 | -10.817 | -28.726 | -24.931 | -31.371 | 0 |
| Income Before Tax Ratio
| -1.799 | -3.096 | -3.43 | -0.631 | -0.655 | -1.094 | 0 | 0 | 0 | 0 | -0.005 | 0 | 0 | 0 | 0 | -15,685.5 | 0 |
| Income Tax Expense
| 0 | 54.158 | 49.716 | 22.638 | 11.857 | 2.875 | 2.132 | 1.672 | 1.06 | 0.229 | 1.131 | 1.403 | 0.501 | 2.071 | 0.468 | 4.104 | -0.332 |
| Net Income
| -209.248 | -287.817 | -318.824 | -166.189 | -109.022 | -201.81 | -166.988 | -74.978 | -49.784 | -36.375 | -26.088 | -11.742 | -10.817 | -28.726 | -24.931 | -27.576 | -10.67 |
| Net Income Ratio
| -1.799 | -3.813 | -4.064 | -0.73 | -0.735 | -1.094 | 0 | 0 | 0 | 0 | -0.005 | 0 | 0 | 0 | 0 | -13,788 | 0 |
| EPS
| -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -1.71 | -1.22 | -1.13 | -6.86 | -6.38 | -9.35 | -7.94 |
| EPS Diluted
| -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -1.7 | -1.22 | -1.13 | -6.86 | -6.38 | -9.35 | -7.94 |
| EBITDA
| -150.108 | -176.349 | -222.143 | -120.334 | -88.726 | -204.32 | -166.532 | -74.35 | -49.028 | -36.064 | -22.688 | -10.116 | -10.062 | -27.215 | -26.804 | -25.522 | -11.685 |
| EBITDA Ratio
| -1.29 | -2.343 | -2.84 | -0.531 | -0.6 | -1.109 | 0 | 0 | 0 | 0 | -0.005 | 0 | 0 | 0 | 0 | -10,861.5 | 0 |